NICE recommends Tremfya


NICE has approved Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis. NICE says guselkumab, which is the first biologic to selectively target interleukin (IL)-23, can be used if:

• The disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 101

• The disease has not responded to other systemic therapies, including PUVA, ciclosporin and methotrexate, or these options are contra-indicated or not tolerated.

Recommended

Paracetamol, pregnancy and language

Exposure to paracetamol during pregnancy seems to increase the risk of language delay in girls, but not boys

Warfarin may cut cancer risk

Research suggests warfarin may have anti-cancer potential. Could this have implications for anticoagulation patients?




This website is for healthcare professionals only. By clicking "Accept" to hide this message or by clicking into any content on this website, you confirm you are a healthcare professional, consent to accepting cookies in accordance with our Cookie Policy and agree to Pharmacy Magazine’s Terms of Use and Privacy Policy.